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ABSTRACT
Introduction. ABO-incompatible liver transplantation (ABOi LT) is considered to be a
rescue option in emergency transplantation. Herein, we have reported our experience with
ABOi LT including long-term survival and major complications in these situations.
Patient and Methods. ABOi LT was performed in cases of severe hepatic failure with
imminent death. The standard immunosuppression consisted of basiliximab, corticoste-
roids, tacrolimus, and mycophenolate mofetil. Pretransplantation patients with anti-ABO
titers above 16 underwent plasmapheresis. If the titer was above 128, intravenous
immunoglobulin (IVIG) was added at the end of plasmapheresis. The therapeutic
approach was based on the clinical situation, hepatic function, and titer evolution. A rapid
increase in titer required five consecutive plasmapheresis sessions followed by adminis-
tration of IVIG, and at the end of the fifth session, rituximab.
Results. From January 2009 to July 2012, 10 patients, including 4 men and 6 women of
mean age 47.8 years (range, 29 to 64 years), underwent ABOi LT. At a mean follow-up of
19.6 months (range, 2 days to 39 months), 5 patients are alive including 4 with their original
grafts. One patient was retransplanted at 9 months. Major complications were infections,
which were responsible for 3 deaths due to multiorgan septic failure (2 during the first
month); rejection episodes (4 biopsy-proven of humoral rejections in 3 patients and 1
cellular rejection) and biliary.
Conclusion. The use of ABOi LT as a life-saving procedure is justifiable in emergencies
when no other donor is available. With careful recipient selection close monitoring of




iACUTE hepatic failure (AHF) is associated with a highmortality rate. Emergency orthotopic liver transplan-
tation (OLT) is the only durable life-saving treatment
beyond the transitory supportive means of a critical care
unit. ABO-incompatible liver transplantation (ABOi LT)
which was reported in 1972 by Starz,1 has gained acceptance
n Asia,2 North America,3 and Europe.4 Japan, the leading
country performing ABOi LT to overcome the organs
shortage, has investigated desensitization strategies.2,5
ABOi transplantation remains a high-risk procedure per-
formed only in cases lacking an available/compatible organ
donor6 or as a rescue option in emergency situations with
the unavailability of a compatible graft.7–11
Early results with adult ABOi LT were disappointing;
patient and graft survivals were significantly worse than
0041-1345/13/$–see front matter
http://dx.doi.org/10.1016/j.transproceed.2013.02.012
1110dult compatible OLT.2,9,10 In 1988, Demetris et al re-
orted a 46% graft failure rate during the first 30 days after
rimary ABOi LT compared with 11% with ABO compat-
bility.12 In 1990, Guggenheim’s group reported 30% graft
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ABO-INCOMPATIBLE LIVER TRANSPLANTATION 1111function at 2 years after transplantation, whereas it was
76% for compatible ABO transplantations.7 The worse
utcomes related to the potential for antibody-mediated
ejection (AMR) associated with the presence of agglutinin
ntibodies.12–15 Vascular thrombosis, acute liver necro-
is,11–14 intrahepatic biliary complications,16–18 and sepsis
caused by over-immunosuppression have been recognized
to be causes of the poor outcomes.5,14 Recently, some
uthors have reported similar patient and graft survivals for
BOi LT compared with compatible OLT among all age
roups.4,5,11,19 Two-year adult recipient survival after ABOi
T was reported to be nearly 70%, whereas before 2002, it
as approximately 40%.5 Similar data have also been
eported in a review of the Organ Procurement and Trans-
lantation Network (OPTN) in 2009.3
In most clinical studies, two main strategies have been
tested in combination to reduce antibody-mediated compli-
cations and prevent or ameliorate lesions caused by antigen-
antibody reactions. Recipient performed isoagglutinins can
be reduced by plasmapheresis.6,13,14,19–21 or by immunoad-
sorption22,23 with adjunctive treatment by splenectomy
nd/or rituximab. 4,5,14,14,24
In 2009, our insitution implemented the current protocol
for ABOi LT for patients with AHF and multiorganic
failure (MOF) who are judged to be unable to wait for a
compatible graft.
PATIENTS AND METHODS
From January 2009 to July 2012, we performed 10 ABOi OLT: 4
men, 6 women, with mean age 47.8 years (range 29 to 64 years).
During the same period, we performed a total of 300 liver
transplantations. The demographic and clinical characteristics of
the 10 ABOi LT patients are summarized in Table 1.
The indications for OLT in patient 1 were AHF secondary to
imatinib treatment for chronic myeloid leukemia. Patients 2, 6, and
8 required retransplantation because of AHF. Patient 2 secondary
to Budd-Chiari syndrome at 3 years after the first transplantation in
the context of polycystic liver disease. Patient 6 secondary to failure
of a first (at 3 months) and a second (at 9 days) transplantation in
the context of chronic hepatic disease secondary to hepatitis B virus
(HBV) and hepatitis C virus. In patient 8, AHF was a result of






1 29 F 33 Toxic Imatinib
2 58 F 39 Retransplant Acute BCS
3 52 F 37 AHF
4 32 F 50 AHF
5 43 M 53 Toxic: Amanitas Phalloide
6 53 M 31 Retransplant HCV, HBV
7 38 F 29 AHF
8 64 M 19 Retransplant Alcoholic, HC
9 52 F 35 Autoimmune
0 58 M 44 AHFAbbreviations: MELD, model for end-stage liver disease; PMT, prometheus; PSE, Po
failure; HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinomalready treated with quimioembolization. In the second case,
failure of a first (at 3 months) and a second (at 9 days) transplan-
tation in the context of chronic hepatic disease secondary to
hepatitis B virus (HBV) and hepatitic C virus. In the third case,
hepatocellular carcinoma (HCC) as a result of alcoholic cirrhosis
and a single hepatocellular carcinoma nodule already treated with
quimioembolization. Patients 3, 4, 7, and 10 developed AHF due to
unknown causes. Patient 5 had AHF secondary to Amanita phal-
loides; patient 9, secondary to autoimmune hepatitis.
Donor-to-recipient ABO matches were AB to O, (n 4; 40%)
A to 0 (n  2; 20%), A to B (n  2; 20%) A to 0 (n  1; 10%)
nd B to A (n  1; 10%).
The patients all displayed severe hepatic failure with an average
odel for end-stage liver disease (MELD) score of 37 (range, 19 to
3). They were listed for OLT on appeal, but progressive worsening
f their clinical conditions associated with MOF and hemodynamic
nstability did not allow a delay in the timing of OLT. At the time
f transplantation, 3 (30%) received dialysis, 7 (70%) patients at
east one session of prometheus, 7 (70%) were ventilated, and 8
80%) were under aminergic support.
Immunosuppressive Protocol
Our protocol was based on those reported in the literature for
ABOi kidney transplantation and ABOi LT using living donors.
The immunosuppressive regimen consisted of induction therapy
with Basiliximab (Simulect, Novartis, Basel V; 20 mg/iv on days 1
and 4; methylprednisolone (500 mg/iv) on the first 3 days switched
to oral prednisolone a (1 mg/kg/d; maximum 60 mg/d), tapered
progressively); tacrolimus (Prograf, Astellas Pharma, Tokyo,
Japan; of 0.05 mg/kg) between days 1 and 4 progressively adjusted
to achieve trough levels of 8 to 12 ng/mL. Thereafter, the target was
reduced to approximately 7 ng/mL; and mycophenolate mofetil
(CellCept, Roche Pharmaceuticals, Basel, Switzerland) adminis-
tered at the daily dose of 1 g, started on the third postoperative day.
Tacrolimus and mycophenolate mofetil were first given intrave-
nously, then switched to oral administration with the resumption of
oral intake.
Related to the ABO incompatibility, the recipient’s hemaggluti-
nin titer, anti-A and anti-B, measurements were performed before
OLT. Test erythrocytes suspended in serial doubling dilutions of
recipient serum were centrifuged and evaluated for agglutination.
The greatest unequivocally positive dilution was defined as the
anti-A or -B antibody titer. ABO titers above 16 underwent
plasmapheresis pretransplantation. The rationale for preoperative





Donor PMT LSE Ventilated
Aminergic
Support
O AB Yes 3 Yes Yes
O AB No 2 Yes Yes
O AB Yes 3 Yes Yes
O A Yes 4 Yes Yes
B A No 3 No No
O A Yes 1 Yes Yes
O A Yes 2 No No
B A1 No 4 Yes Yes
A B Yes 4 No Yes
O AB Yes 3 Yes Yesnt Ch
s
Crtosystemic encephalopathy; BCS, Budd-chain syndrome; AHF, acute hepatic
a.
11112 MENDES, FERREIRA, FERREIRA ET ALit there after OLT was derived from the kidney transplant litera-
ture. Titers above 128 were treated with intravenous immunoglob-
ulin IVIG (2 g/kg) administered after the plasmapheresis. Hemag-
glutinin titers were performed daily posttransplantation for at least
21 days. The therapeutic approach was determined according to
the clinical situation, the hepatic function, and the evolution of the
ABO titers. Rapid increasing titers implied at least five consecutive
plasmapheresis sessions followed by administration of IVIG (400
mg/kg/d) after each one. At the end of the fifth session we infused
rituximab (375 m/m2).
Dual needle plasmapheresis procedures were performed to
1.0–1.5 exchange of the calculated plasma volumes using 100%
fluid balances. The replacement fluids for plasma exchanges—fresh
frozen plasma and 5% human albumin—and their ratios were
based on coagulation parameters.
The immunosuppressive regimen in each patient was heterogen-
erous (Table 2) because the protocol was adjusted to the clinical
status of the patient, namely, hemodynamic instability or presence
of infection.
Histology
Whenever clinical or biological signs suggested rejection, we per-
formed liver biopsies. All liver biopsy specimens were subjected to
paraffin block immunohitochemistry for complement derivative 4d
(C4d), hemagglutin deposition, and cytotoxic antibodies in sinu-
soids to investigate AMR. Acute cellular rejection (ACR) was
defined according to Banff criteria.
Infection Prophylaxis
Antimicrobial prophylaxis consisted of piperacilin-tazobactam
(4.5 g) every 8 hours for at least a week. For cytomegalovirus
antiviral prophylaxis, the patients received valganciclovir (900










1 64 128 1 No 8 PP, 1 IvIG, 3
64 2048 4
2 16 128 16 Yes PP, IVIg 3 MTP, 14 P P
128 256 8
3 32 256 64 No 10 IVIg
32 512 4


















No 1 RTX, 1 IVIG
7 64 256 4
—
Yes 5PP, 1 IVIg, 1 R
128 512 PP
8 64 128 1 Yes —
64 2048 4 PP
9 32 128 16 Yes —
— — — RTX
0 16 126 16 No 2 RTX, 6 PP, 4
16 16 1
*Retransplanted.
Abbreviations: ACR, acute cellular rejection; AMR, antibody mediated rejection; PP
RTX, rituximab.administration of amphotericin B lipid complex (1 mg/kg/d) for the
first week, then 2.5 mg/kg twice a week for an additional 3 weeks.
Pneumocystis Jiroveci prophylaxis consisted (480 mg/d) of trim-
ethoprim/sulfamethoxazole (480 mg/d). Doses were adjusted to
patient clinical status and laboratory results.
RESULTS
At a mean follow-up of 19.6 months (range, 2 days-39
months), 5 patients are alive, 4 of them carrying the original
graft (Table 2). Patient survival was 50% and graft survival,
40%.
Complications
Histology. Among the biopsies performed, four in 3
patients revealed AMR (an Table 2); 1 ACR, and the other
in the same subject (patient 5) chronic rejection with an
acute component. One biopsy (patient 9) showed ischemic
changes.
Late biliary complications. Patients 1 and 5 presented
sclerotic changes in the intrahepatic ducts at cholangiogra-
phy. Patient 2 had to be retransplanted at 9 months
follow-up due to jaundice secondary to severe biliary com-
plications. Patient 9 showed biliary complications at cholan-
giography before retransplantation.
Death. Five of our patients died after ABOi LT; 3 due to
an infection acquired prior to OLT. Patient 3 died at 30
days after transplantation due to multiple septic emboli in
the brain; A retrospective analysis of the pretransplantation
examinations revealed probable pneumonia as the primary







, 2 RTX — 1 Yes 39 Alive
Ig 4 RTX — 1 Yes 9 Alive*
— — — 1 Decrease
— — — 26 Alive
1 — Yes 17 Deceases
— — — 11 days Deceases
— — — 11 Alive
— — — 2 days Decease
— — Yes 14 days Decease*























ABO-INCOMPATIBLE LIVER TRANSPLANTATION 1113septic MOF on the 11th day after transplantation, suffering
recurrent severe systemic infections. Concurrent to OLT
ongoing bronchoalveolar lavage and blood cultures showed
Pheumocystis Jiroveci plus methicillin-resistant Staphylococ-
us aureus isolation. Patient 5 died due to septic MOF at 17
onths follow-up probably secondary to chronic immuno-
uppression. Patient 8 died on the 2nd day after transplan-
ation. He had undergone a first transplantation 2 months
rior with several complications thereafter. He presented
ith severe ischemia of the first graft and was in multiorgan
hock at the time of the second transplantation.
Patient 9 was retransplanted with an ABO compatible
raft at 14 days due to severely ischemic liver eventually
uccumbing on the 10th day after the second transplanta-
ion due to an hepatic artery thrombosis.
Other infections. Patient 1 presented a cytomegalovirus
CMV) infection in the immediate posttransplantation pe-
iod. Patient 7 had Staphylococcus Epidermidis isolated in
blood cultures and Escherichia coli and Enterococcus Faeca-
lis in the urine. He also presented CMV infection. Patient 9
presented a Pneumocystis Jiroveci infection.
DISCUSSION
We have described 10 adult emergent ABOi LT patients
who displayed 50% survival despite their severe critical
illnesses. It is known that an emergency procedure itself
carries higher risk of complications and worse long-term
outcomes compared with liver transplantations in nonur-
gent candidates related to the degree of illness. Published
1-year survival rates have ranged widely from 58% to
92%.25
In a study of 234 liver transplants, Guggenheim reported
2-year graft survivals for ABO compatible elective (80%)
versus emergency (76%) liver transplantation to be signifi-
cantly higher than for ABOi emergency liver transplanta-
tions (30%). The poor survival of ABOi LT is therefore
related to blood group incompatibility and immunologic
damage.7 Although ABOi grafts are associated with poor
graft survival, long-term patient survival is still good at the
cost of a high rate of retransplantations.8–10 Recently, Toso
et al. did not observe a significant difference regarding
patient and graft survival when comparing 1- and 5-year
data from ABOi, ABO compatible and ABO identical
livers.11
The main complication of ABOi LT is AMR, closely
related to high levels of anti-donor ABO antibodies present
perioperative and posttransplant. As a result, most efforts
to improve ABOi LT outcome have been directed to
reducing anti-blood type antibodies.14,26 As a result, most
efforts to improve the outcome of ABOi LT have been
directed toward lowering anti-blood type antibodies.
We registered four AMR episodes in 3 patients which
were all reversible with immunosuppression. This observa-
tion is consistent with the literature, as immunological
damage is potentially reversible when AMR is mild. It
becomes irreversible when there is massive hepatocyteecrosis secondary to vascular thrombosis.12,14 These ob-
servations reinforce the need for close monitoring of isoag-
glutinin levels, especially during the first month and argue
for prophylactic institution of immunosuppression when
levels increase.4,11,13,28
We cannot confirm that AMR was directly associated
with a higher titer of anti-ABO antibodies. Patients 4 and 5
with elevated titers showed no evidence of AMR or other
complications, possibly as a consequence of effective inter-
ventions. In addition, patient 9 with relatively low levels
experienced biliary complications. The poor positive pre-
dictive value of elevated posttransplantation titers has been
already reported in otherwise stable ABOi recipients.26
There was progressive normalization of the titers after
the first month. In fact, 1 month after OLT, most patients
presented anti-ABO titers lower than those pretransplan-
tation, whereas others were progressively decreasing. We
suppose that the risk of graft dysfunction is mainly present
during the first month, tending to vanish later. This is
probably related to partial replacement of graft vasculature
by endothelial cells that no longer carry foreign ABO
antigens and or to a process of immunological accommo-
dation.21,27
In our experience, blood type O recipients seemed to be
associated with a higher risk of AMR after ABOi LT
because rejection episodes happened among these recipi-
ents. Blood type O is described in the literature as a
significant risk factor for AMR in adults. Group O patients
not only produce immunoglobulin (Ig)M anti-A anti-B, but
also a greater degree of T-helper cells, and greater switch-
ing to a broader array of IgG subclasses.28
In addition to AMR, hepatic artery and biliary compli-
cations have been recognized to be the major causes of poor
outcomes among these patients. The increased incidence of
biliary complications observed in the ABOi group may be
related to direct immunological mechanisms, as bile ducts
epithelium can also express ABO antigens, being a target
for antibody-mediated injury.15–17
A standard therapy was maintained with tacrolimus,
mycophenolate mofetil, and prednisolone following basilix-
imab induction. Pre- and postoperative plasmapheresis
targeted isoagglutinin titers of at most 1:16, with or without
IVIG and rituximab which were used to deplete cells
producing IgM antibodies and those mediating HLA
antibody–drives rejection episodes.13,24,29
Although splenectomy has been used in desensitization
protocols for ABOi transplantation,21 it seems that AMR
an be avoided with scheduled rituximab prophylaxis or
ultidrug immunosuppression.14,23 Splenectomy avoidance
decreases the risk of portal vein thrombosis19 and long-term
lethal infections.6,23 We also have avoided intrahepatic
infusions (portal or arterial) proposed by some authors to
control local and disseminated intravascular coagulation.5,6
Although the recent development of immunosuppression
has decreased AMR, the incidence of bacterial infections
has increased becoming the most significant cause of death



































































1114 MENDES, FERREIRA, FERREIRA ET ALwas infection with the major consequence of MOF resulting
in the deaths of 3 patients.
A2 to 0 transplants should be favored when possible, as
the antigenic expression of the A2 phenotype is quantita-
tively and qualitatively different than the A1 phenotype,
inducing a weaker immune response.30–32
International series have reported that recipient age
seems to be a key factor in the outcomes of ABOi LT. We
already know that recipients age is significantly related to
AMR and that pediatric ABOi LT do not show worse graft
survivals versus age-matched OLT.3,5,33
These two circumstances, age and donor A2, may permit
successful liver transplantations with similar overall and
graft survivals even without desensitization.30 This opens
ossibilities to further meet the demands, given the current
rgan shortage, especially with regard to expanding living-
onor options.
Three of our ABOi LTs were retransplantations. 2 died
nd the other needed a new transplantation. The specific
elated circumstances leading to worse outcomes in this
ituation, have also been reported in other series,10,11
suggesting that the use of ABOi grafts for retransplantation
may present an even greater challenge, and should be
considered only with caution.
In conclusion, the use of ABOi liver grafts can be life saving.
They should be offered to all patients in emergent need when
no other donors are available. Such transplantations may help
to save the patient even at the cost of retransplantation. Our
findings support that with careful recipient selection, based on
expanding experience and modern immunosuppressive proto-
cols, acceptable outcomes can be obtained. We advocate
further expansion to improve the efficacy and safety of
ABOi-LT via multicenter trials.
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